Mississauga - GenomeArc, a leader in clinical genomics and personalized medicine, proudly announces a major breakthrough with its HORIZON platform. The latest advancement enables the completion of ACMG guided tertiary analysis of a whole human long read genome (~5 million variants vcf) in a record time of just 10 minutes, marking a significant milestone in genetic diagnostics and targeted therapeutics. This acceleration facilitates scrutinizing population-scale projects with enhanced clarity, delving into the intricacies of each sample and genome.

Dr. Mohammed Uddin Dafil, Founder of GenomeArc, expressed his excitement about this breakthrough. "The ability to perform tertiary analysis in 10 minutes is a game-changer for clinicians and patients alike. This rapid turnaround allows for quicker decision-making, potentially leading to faster initiation of targeted treatments and improved patient outcomes, especially for critical care (NICU/PICU) and cancer patients".

As a user, Dr. Nasna Nassir, Scientist at Dubai Health, highlighted the clinical impact of this advancement. "Horizon's swift analysis accelerates clinical diagnosis in critical care and cancer genomics, marking a significant leap from current analysis time. This advancement helps the lab with quicker, precise decisions and clinical management in patient care".

GenomeArc HORIZON’s accelerated tertiary analysis supports the growing trend towards implementing precision medicine, to enable precise diagnosis and personalize treatment options based on the genetic profile of patients. GenomeArc HORIZON has consistently been at the forefront of clinical genomics, providing robust solutions for genetic diagnosis and the development of targeted therapies. With the latest update, HORIZON further solidifies its position as a pioneering platform in the field, dramatically reducing the time required for tertiary analysis from hours to mere minutes.